This website is intended for healthcare professionals only.

Hospital Healthcare Europe
Hospital Pharmacy Europe     Newsletter          

Genmab announces European regulatory submission for ofatumumab for relapsed CLL

Genmab A/S announced that a variation to the Marketing Authorisation has been submitted to the European Medicines Agency (EMA) for the use of ofatumumab (Arzerra®) as maintenance therapy of patients with relapsed chronic lymphocytic leukaemia (CLL).

The application was submitted by Novartis under its ofatumumab collaboration.

The application is based on interim results from a Phase III study, PROLONG (OMB112517) which evaluated ofatumumab maintenance therapy versus no further treatment in patients with a complete or partial response after second- or third-line treatment for CLL.  Results from this trial were presented at the 2014 American Society of Hematology Annual Meeting.

The PROLONG study showed the potential of using ofatumumab as an ongoing maintenance therapy for patients with relapsed CLL. We are pleased that Novartis has taken the next step with ofatumumab in this setting by submitting a regulatory application to the EMA,” said Jan van de Winkel, PhD, Chief Executive Officer of Genmab.

About CLL
CLL, the most commonly diagnosed adult leukaemia in Western countries, accounts for approximately 1 in 4 cases of leukaemia. (1,2) Most CLL patients experience disease progression despite initial response to therapy and may require additional treatment. (3)

About Ofatumumab (Arzerra®)
Ofatumumab is a human monoclonal antibody that is designed to target the CD20 molecule found on the surface of chronic lymphocytic leukaemia (CLL) cells and normal B lymphocytes.

In the United States, Arzerra is approved for use in combination with chlorambucil for the treatment of previously untreated patients with CLL for whom fludarabine-based therapy is considered inappropriate. In the European Union, Arzerra is approved for use in combination with chlorambucil or bendamustine for the treatment of patients with CLL who have not received prior therapy and who are not eligible for fludarabine-based therapy. In more than 50 countries worldwide, Arzerra is also indicated as monotherapy for the treatment of patients with CLL who are refractory after prior treatment with fludarabine and alemtuzumab.

Arzerra is not approved anywhere in the world as maintenance therapy for relapsed chronic lymphocytic leukaemia.
Please see full Prescribing Information, including Boxed WARNING for Arzerra (ofatumumab).

Arzerra is marketed under a co-development and collaboration agreement between Genmab and Novartis, as successor in interest to GSK.